G&E’s antitrust practice group concentrates on complex antitrust class and individual actions. Firm attorneys have collected settlements and judgments on behalf of classes and individuals totaling well over a billion dollars.

Recovery Amount
Card Interchange
In re Payment Card Interchange Fee and Merchant Discount Antitrust Litigation

Eastern District of New York

G&E represents numerous major merchants in an antitrust action against Visa and MasterCard. In June 2005, these retail chains filed private antitrust suits related to credit card interchange fees. Class action lawsuits were also filed, and all of the cases were centralized in the Eastern District of New York. The suits allege that Visa and MasterCard have engaged in collusive practices to fix the interchange fees at artificially high rates, and that certain rules promulgated and enforced by Visa and MasterCard are anticompetitive and artificially increase the interchange fees paid to card issuing banks by the merchants. On October 4, 2010, the Department of Justice (“DOJ”) sued Visa and MasterCard for much of the conduct alleged in the pending suits, using the record that the private plaintiffs had developed to bring its litigation. On that same day, both Visa and MasterCard entered into consent agreements with the DOJ.

Castro, et al. v. Sanofi Pasteur, Inc.

District of New Jersey

Plaintiffs brought this antitrust class action on behalf of physicians and other health care providers nationwide against Sanofi Pasteur, alleging that the defendant monopolized U.S. markets for a number of pediatric vaccines, including pediatric meningitis vaccines.  Plaintiffs allege that Sanofi abused its monopoly power by engaging in unlawful bundling practices, requiring physicians to either pay a penalty price or purchase an entire bundle of various Sanofi vaccines in order to obtain Sanofi’s meningitis vaccine, Menactra. As a result of this bundling scheme, plaintiffs allege that physicians and health care providers nationwide were overcharged for pediatric vaccine purchases. In addition to moving to dismiss, Sanofi took the highly unusual step of filing a counterclaim against all members of the proposed class that would claim proceeds from any settlement. Plaintiffs successfully opposed the motion to dismiss and obtained dismissal of Sanofi’s counterclaim. Discovery is proceeding.